ZA200707141B - Pyridine-2-Carboxamide derivatives as mGluR5 antagonists - Google Patents

Pyridine-2-Carboxamide derivatives as mGluR5 antagonists

Info

Publication number
ZA200707141B
ZA200707141B ZA200707141A ZA200707141A ZA200707141B ZA 200707141 B ZA200707141 B ZA 200707141B ZA 200707141 A ZA200707141 A ZA 200707141A ZA 200707141 A ZA200707141 A ZA 200707141A ZA 200707141 B ZA200707141 B ZA 200707141B
Authority
ZA
South Africa
Prior art keywords
pyridine
carboxamide derivatives
mglur5 antagonists
mglur5
antagonists
Prior art date
Application number
ZA200707141A
Other languages
English (en)
Inventor
Jaeschke Georg
Porter Richard Hugh Philip
Kolczewski Sabine
Vieira Eric
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36524927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200707141(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200707141B publication Critical patent/ZA200707141B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
ZA200707141A 2005-03-04 2007-08-23 Pyridine-2-Carboxamide derivatives as mGluR5 antagonists ZA200707141B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05101701 2005-03-04

Publications (1)

Publication Number Publication Date
ZA200707141B true ZA200707141B (en) 2008-10-29

Family

ID=36524927

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200707141A ZA200707141B (en) 2005-03-04 2007-08-23 Pyridine-2-Carboxamide derivatives as mGluR5 antagonists

Country Status (17)

Country Link
US (2) US7414060B2 (ja)
EP (1) EP1858854B1 (ja)
JP (1) JP4767975B2 (ja)
KR (1) KR100929942B1 (ja)
CN (1) CN101133027B (ja)
AR (1) AR054232A1 (ja)
AU (1) AU2006222289A1 (ja)
BR (1) BRPI0607583A2 (ja)
CA (1) CA2599974C (ja)
ES (1) ES2476840T3 (ja)
IL (1) IL185326A0 (ja)
MX (1) MX2007010414A (ja)
NO (1) NO20074258L (ja)
RU (1) RU2411237C2 (ja)
TW (1) TW200700391A (ja)
WO (1) WO2006094639A1 (ja)
ZA (1) ZA200707141B (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0607583A2 (pt) * 2005-03-04 2009-09-15 Hoffmann La Roche derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos
US20060199828A1 (en) * 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
RU2008129622A (ru) * 2005-12-20 2010-01-27 Новартис АГ (CH) Производные никотиновой кислоты в качестве модуляторов метаботропных глутаматных рецепторов
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
MX2010003913A (es) * 2007-10-12 2010-04-27 Novartis Ag Moduladores de los receptores de glutamato metabotropicos para el tratamiento de enfermedades de parkinson.
WO2009047303A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of pervasive developmental disorder
WO2009078432A1 (ja) * 2007-12-18 2009-06-25 Taisho Pharmaceutical Co., Ltd. １-アルキル-４-アミノ-１ｈ-ピラゾール-３-カルボキサミド化合物
WO2010100050A1 (en) * 2009-03-05 2010-09-10 F. Hoffmann-La Roche Ag Pyridine-2-yl-carboxylic acid amides
EP2477492A4 (en) * 2009-09-17 2013-05-01 Univ Vanderbilt SUBSTITUTED CARBOXAMIDE HETEROARYLAMINE ANALOGUES AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS, METHODS FOR PREPARING AND USING SAME
JP2013508412A (ja) 2009-10-22 2013-03-07 ヴァンダービルト ユニバーシティー ｍＧｌｕＲ４アロステリック増強剤、組成物、および神経機能不全を治療する方法
US8470820B2 (en) * 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
BR112012025242B1 (pt) 2010-04-06 2018-04-17 Nippon Soda Co., Ltd. Método para produção de um derivado de amino-6- metilpiridino-n-óxido substituído
AU2014201038B2 (en) * 2010-04-06 2015-08-06 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic compound and method for producing same
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
WO2015077246A1 (en) 2013-11-19 2015-05-28 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mglur5
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
CA3090545A1 (en) 2018-02-28 2019-09-06 University Of Southern California Compositions and methods for modulating inflammatory and degenerative disorder
CN112624968B (zh) * 2021-01-18 2022-03-08 阿里生物新材料（常州）有限公司 一种5-氨基-3-氰基吡啶甲酸甲酯盐酸盐的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
NZ515894A (en) * 1999-06-02 2003-09-26 Nps Pharma Inc Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
JP4573533B2 (ja) * 2002-03-29 2010-11-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 放射能標識付きキノリンおよびキノリノン誘導体および代謝向性グルタメート受容体リガンドとしてのそれらの使用
ATE517887T1 (de) 2003-02-13 2011-08-15 Msd Kk Neue 2-pyridincarbonsäureamidderivate
CN101712657A (zh) 2003-02-26 2010-05-26 万有制药株式会社 杂芳基氨基甲酰基苯衍生物
JP2006521358A (ja) * 2003-03-26 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体のベンズアミドモジュレータ
US20070149547A1 (en) * 2004-02-12 2007-06-28 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
BRPI0607583A2 (pt) * 2005-03-04 2009-09-15 Hoffmann La Roche derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos

Also Published As

Publication number Publication date
KR100929942B1 (ko) 2009-12-04
MX2007010414A (es) 2007-09-25
WO2006094639A1 (en) 2006-09-14
BRPI0607583A2 (pt) 2009-09-15
CN101133027B (zh) 2011-03-30
RU2007132655A (ru) 2009-04-10
US20060199960A1 (en) 2006-09-07
CA2599974A1 (en) 2006-09-14
JP2008531618A (ja) 2008-08-14
US7414060B2 (en) 2008-08-19
AU2006222289A1 (en) 2006-09-14
RU2411237C2 (ru) 2011-02-10
TW200700391A (en) 2007-01-01
IL185326A0 (en) 2008-02-09
EP1858854A1 (en) 2007-11-28
EP1858854B1 (en) 2014-05-07
CA2599974C (en) 2013-12-31
AR054232A1 (es) 2007-06-13
CN101133027A (zh) 2008-02-27
ES2476840T3 (es) 2014-07-15
KR20070107102A (ko) 2007-11-06
US20080269256A1 (en) 2008-10-30
JP4767975B2 (ja) 2011-09-07
NO20074258L (no) 2007-11-27

Similar Documents

Publication Publication Date Title
IL185326A0 (en) PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS
ZA200705670B (en) Thiazole-4-carboxamide derivatives as mGluR5 antagonists
IL185692A0 (en) Acetylenyl-pyrazolo-pyrimidine derivatives as mglur2 antagonists
ZA200707139B (en) Pyrazine -2-carboxamide derivatives as mGluR5 antagonists
ZA200803811B (en) Neuropolin antagonists
HK1124233A1 (en) Quinoline derivatives as antibacterical agents
HUS2000022I1 (hu) Tiglien-3-on származékok
HK1129305A1 (zh) 取代的 -氨基-吡咯並三嗪衍生物
AP2007004047A0 (en) Substituted triazole derivatives as oxtocin antagonists
EP1878727A4 (en) 2-AMINOQUINAZOLINE DERIVATIVES
ZA200806809B (en) Pyridine-2-carboxamide derivatives
HK1115321A1 (en) Camptothecin derivatives as chemoradiosensitizing agents
ZA200706353B (en) Pyrazolo-pyrimidine derivatives as mGluR2 antagonists
IL192092A0 (en) Aryl-isoxazolo-4-yl-oxadiazole derivatives
IL185674A0 (en) 1-benzylindole-2-carboxamide derivatives
ZA200710343B (en) Bicyclic derivatives as p38 kinase inhibitors
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
SI2069310T1 (sl) Sulfonilpirazolin-1-karboksamidinski derivati kot 5-HT6 antagonisti
IL184841A0 (en) Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives
IL192308A0 (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
IL188027A0 (en) Bicyclic derivatives as p38 kinase inhibitors
IL187410A0 (en) Quinoline derivatives as nk3 antagonists
IL182739A0 (en) Acylatednonadepsipeptides used as lysobactin derivatives
ZA200803454B (en) Piperazine derivatives useful as CCR5 antagonists
HUP0501169A3 (en) New phenantridine derivatives as selective bradykinin b1 receptor antagonists